Adaptive Biotechnologies ADPT Mrd Business — Research And Development Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Adaptive Biotechnologies's mrd business — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Adaptive Biotechnologies's mrd business — research and development expense?
- Adaptive Biotechnologies (ADPT) reported mrd business — research and development expense of $9.23M in Q1 2026.
- How has Adaptive Biotechnologies's mrd business — research and development expense changed year-over-year?
- Adaptive Biotechnologies's mrd business — research and development expense increased by 0.7% year-over-year, from $9.16M to $9.23M.
- What is the long-term trend for Adaptive Biotechnologies's mrd business — research and development expense?
- Over 3 years (2022 to 2025), Adaptive Biotechnologies's mrd business — research and development expense has grown at a 3.3% compound annual growth rate (CAGR), from $31.77M to $35.03M.
- What does mrd business — research and development expense mean?
- This reflects the investment in scientific research, clinical trials, and product development specifically allocated to the MRD business segment. It measures the company's commitment to innovation and the expansion of its diagnostic pipeline to maintain a competitive edge in immune-driven medicine.